RegeneRx Biopharmaceuticals, Inc. announced that its licensee for RGN-137, GtreeBNT, has entered into a joint venture with YuYang DNU, a Korean company, to develop RGN-137 on a global basis for the orphan indication, epidermolysis bullosa (EB).
August 2, 2018
· 4 min read